Question 1

What are the most cited papers from Cytovac (Denmark)?

Accepted Answer

The most cited paper from Cytovac (Denmark) is "Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells" (Alexei F. Kirkin, Karine N. Dzhandzhugazyan, Per Guldberg et al., 2018), with 52 citations. Next come "Adoptive T cell cancer therapy" (27) and "Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis" (15).

Question 2

Which research topics does Cytovac (Denmark) publish most on?

Accepted Answer

By volume in 2022-now: Phagocytosis and Immune Regulation, CAR-T cell therapy research, Immunotherapy and Immune Responses and Immune cells in cancer.

Question 3

Which fields of science does Cytovac (Denmark) work in?

Accepted Answer

In all years, 54% of research at Cytovac (Denmark) is in Life Sciences, 46% in Health Sciences. Its largest fields are Immunology and Microbiology (46%), Medicine (46%), Biochemistry, Genetics and Molecular Biology (8%).

Question 4

Is Cytovac (Denmark)'s research output growing?

Accepted Answer

Output in 2022-2025 was 18% lower than in 2018-2021.